KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Assets Average (2016 - 2025)

Nektar Therapeutics has reported Assets Average over the past 15 years, most recently at $290.9 million for Q4 2025.

  • Quarterly results put Assets Average at $290.9 million for Q4 2025, down 4.91% from a year ago — trailing twelve months through Dec 2025 was $290.9 million (down 4.91% YoY), and the annual figure for FY2025 was $292.1 million, down 16.76%.
  • Assets Average for Q4 2025 was $290.9 million at Nektar Therapeutics, up from $254.4 million in the prior quarter.
  • Over the last five years, Assets Average for NKTR hit a ceiling of $1.5 billion in Q1 2021 and a floor of $231.9 million in Q2 2025.
  • Median Assets Average over the past 5 years was $498.1 million (2023), compared with a mean of $676.1 million.
  • Biggest five-year swings in Assets Average: plummeted 44.01% in 2023 and later fell 4.91% in 2025.
  • Nektar Therapeutics' Assets Average stood at $1.2 billion in 2021, then tumbled by 37.71% to $745.8 million in 2022, then tumbled by 43.67% to $420.1 million in 2023, then dropped by 27.19% to $305.9 million in 2024, then decreased by 4.91% to $290.9 million in 2025.
  • The last three reported values for Assets Average were $290.9 million (Q4 2025), $254.4 million (Q3 2025), and $231.9 million (Q2 2025) per Business Quant data.